The article by Craft et al1 demonstrating that intranasal insulin improves cognitive function and fludeoxyglucose F 18 uptake in specific regions of the brain in patients with mild cognitive impairment and Alzheimer disease (AD) is a landmark study. For the first time, the previous data that AD is both a reflection of a combination of diminished insulin bio-availability and insulin action has been borne out. In addition, the data are consistent with the fact that AD is a chronic inflammatory disease and that insulin exerts a potent anti-inflammatory effect.2
Batra M, Ghanim H, Dandona P. Insulin and Alzheimer Disease. Arch Neurol. 2012;69(5):670–671. doi:10.1001/archneurol.2012.42
Customize your JAMA Network experience by selecting one or more topics from the list below.